| Code | CSB-RA016023MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to REGN-7544, targeting NPR1 (Natriuretic Peptide Receptor 1), also known as NPR-A or GC-A. NPR1 functions as a transmembrane guanylyl cyclase receptor that binds atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), playing crucial roles in cardiovascular homeostasis, blood pressure regulation, and fluid-electrolyte balance. Upon ligand binding, NPR1 generates cyclic GMP, triggering vasodilation, natriuresis, and diuresis. Dysregulation of the NPR1 signaling pathway has been implicated in hypertension, heart failure, cardiac hypertrophy, and various cardiovascular disorders, making it an important therapeutic target for cardiovascular research.
REGN-7544 represents a therapeutic antibody developed for modulating NPR1 activity in cardiovascular disease contexts. This biosimilar provides researchers with a valuable tool for investigating NPR1-mediated signaling pathways, studying natriuretic peptide biology, and exploring potential therapeutic interventions in cardiovascular and renal disorders. The antibody supports various experimental approaches aimed at understanding receptor function, ligand interactions, and downstream signaling mechanisms in relevant disease models.
There are currently no reviews for this product.